Brachytherapy Market

Brachytherapy Market Size

The global Brachytherapy Market size was valued at USD 984.6 million in 2023 and is projected to grow from USD 1049.0 million in 2024 to USD 1760.9 million by 2031, exhibiting a CAGR of 7.68% during the forecast period. The growth of the market is driven by the increasing adoption of personalized medicine, which enhances treatment precision and patient outcomes.

Furthermore, the expansion of healthcare infrastructure and cancer treatment centers globally is boosting market growth. Additionally, the growing investment in research and development is leading to the introduction of innovative brachytherapy solutions. Increased government funding and support for cancer treatment programs are further supporting market expansion.

In the scope of work, the report includes solutions offered by companies such as Eckert & Ziegler, BEBIG, Elekta AB, Theragenics Corp., Becton, Dickinson, and Co., Varian Medical Systems Inc., iCAD Inc., CIVCO Medical Solutions, Sun Nuclear Corp., AngioDynamics Inc., Hologic, Inc., and others.

The brachytherapy market is experiencing robust growth, fueled by ongoing technological advancements and the rising prevalence of cancer globally. The increasing incidence of cancers, particularly prostate, cervical, and breast cancers, underscores the growing need for effective treatment modalities.

• For instance, the American Cancer Society estimates that about 13,820 new cases of invasive cervical cancer are likely to be diagnosed in the United States in 2024, highlighting the demand for targeted treatments such as brachytherapy.

Furthermore, the integration of advanced imaging techniques such as MRI and CT scans is further propelling market expansion by improving tumor visualization and source placement accuracy.

Brachytherapy is a specialized form of radiation therapy that involves placing a radioactive source directly inside or very close to a tumor, allowing for targeted and precise radiation delivery. This method differs from external beam radiation, which directs radiation from outside the body.

By delivering high doses of radiation directly to the cancerous tissue while minimizing exposure to surrounding healthy tissues, brachytherapy enhances treatment efficacy and reduces side effects. It is commonly utilized for treating cancers such as prostate, cervical, breast, and skin cancers. The localized approach of brachytherapy makes it an effective option for managing various malignancies with improved precision.

Analyst’s Review

The increasing focus on expanding treatment options and improving access to specialized therapies is augmenting the growth of the brachytherapy market.

• For instance, in May, 2024, GT Medical Technologies, Inc. (GT MedTech) announced a strategic distribution partnership with Theragenics Corporation. This collaboration aims to expand physician access to Cesium-131 seeds, thereby enhancing the flexibility of brachytherapy procedures. By partnering with a global leader in minimally invasive brachytherapy, GT MedTech seeks to improve treatment options and support for patients with brain tumors, reflecting the growing emphasis on advancing specialized cancer therapies.

Key players are supporting market growth by forming strategic partnerships, expanding product portfolios, and advancing technological innovations in brachytherapy. Investments in training programs and collaborations with industry leaders are improving treatment precision and accessibility, thereby fostering adoption and broadening the reach of specialized cancer therapies.

Brachytherapy Market Growth Factors

The global rise in cancer cases, particularly prostate, cervical, and breast cancers, is leading to increased demand for brachytherapy.

• For instance, the American Cancer Society anticipates the number of new cancer cases globally to reach 21.6 million by 2030, with more than 13 million cancer-related deaths.

This treatment modality is increasingly preferred due to its highly targeted approach, which allows for the precise delivery of radiation directly to the tumor site. By minimizing exposure to surrounding healthy tissues, brachytherapy reduces the risk of collateral damage and associated side effects, thereby enhancing patient safety and comfort.

Its effectiveness in controlling tumor growth and improving survival rates further underscores its importance in cancer treatment protocols. As cancer prevalence continues to rise, the adoption of brachytherapy is expected to grow, thereby boosting the brachytherapy market growth.

The high cost associated with brachytherapy and the lack of skilled professionals are expected to hinder market expansion. Additionally, regulatory obstacles and rigorous approval processes are impeding the timely introduction of new technologies. To mitigate these issues, market players are proactively investing in comprehensive training programs to enhance provider expertise and are collaborating with regulatory agencies to streamline approval workflows.

Moreover, companies are focusing on developing cost-efficient solutions and expanding their product portfolios to improve accessibility and affordability. These strategic initiatives are designed to address existing barriers and stimulate market growth by enhancing service delivery and operational efficiency.

Brachytherapy Market Trends

The development of new brachytherapy technologies, such as minibeads and image-guided delivery systems, represents a significant market trend that is propelling growth in the sector. These innovations enhance treatment accuracy by allowing for precise radiation delivery to the tumor site and providing real-time visualization for optimal placement.

The improved precision and reduced complications associated with these technologies make brachytherapy a safer and more effective option for cancer treatment. As a result, the increased efficacy and safety profile of these advanced brachytherapy techniques are driving higher adoption rates among healthcare providers and patients, thereby fueling the brachytherapy market expansion.

The incorporation of advanced imaging techniques, such as MRI and CT scans, with brachytherapy is emerging as a significant market trend. These imaging methods offer enhanced visualization of tumors and surrounding tissues, facilitating more accurate placement of brachytherapy sources. This improved precision in treatment delivery reduces the risk of radiation exposure to healthy tissues, thereby minimizing side effects and enhancing patient safety.

The widespread adoption of image-guided brachytherapy is contributing significantly to market growth. The ability to achieve better treatment outcomes with these advanced imaging techniques is making brachytherapy an increasingly attractive option for both patients and healthcare providers, thus propelling market expansion.

Segmentation Analysis

The global market is segmented based product type, therapy, dosage type, application, end-user, and geography.

By Product Type

Based on product type, the market is categorized into seeds, applicators and afterloaders, and electronic brachytherapy. The seeds segment garnered the highest revenue of USD 504.0 million in 2023. This growth is fueled by continual advancements in seed technology and increasing demand for targeted cancer treatments.

Seeds containing Cesium-131 or Iodine-125 are being used to deliver precise radiation doses directly to tumors, thereby improving treatment efficacy and reducing side effects. Innovations in seed design and delivery techniques are enhancing treatment precision, thereby prompting an increasing number of healthcare providers to adopt brachytherapy.

Additionally, the growing prevalence of cancers such as prostate and breast, which are often treated with seed-based brachytherapy, is further propelling segmental growth by increasing the need for these effective, minimally invasive treatment options.

By Dosage Type

Based on dosage type, the brachytherapy market is categorized into low-dose rate implants, high-dose rate implants, and permanent implants. The high-dose rate implants segment captured the largest market share of 49.23% in 2023.

HDR brachytherapy involves placing a radioactive source temporarily inside or near the tumor to deliver high doses of radiation over a short period. This approach enhances treatment precision and minimizes exposure to healthy tissues.

The segment is expanding as healthcare providers increasingly adopt HDR implants for their ability to provide effective, targeted therapy for cancers such as prostate, cervical, and breast. Continuous innovations in HDR technology, including improved source delivery systems and enhanced imaging techniques, are further bolstering segmental growth.

By Application

Based on application, the market is categorized into prostate cancer, cervical cancer, breast cancer, lung cancer, rectal cancer, and others. The prostate cancer segment is expected to garner the highest revenue of USD 618.4 million by 2031. Prostate cancer is among the most prevalent cancers in men. Brachytherapy offers a targeted approach to treating this condition by delivering precise radiation directly to the prostate while minimizing exposure to surrounding healthy tissues.

• For instance, a recent publication in the American Brachytherapy Society’s journal, highlights that MRI-assisted radiosurgery using C4 Imaging's Sirius is a valuable approach for prostate brachytherapy.

This technique provides detailed anatomical information for treatment planning, delivery, and quality assurance, thereby enhancing the efficacy of brachytherapy. These advancements are aiding segmental growth by improving treatment outcomes and increasing patient satisfaction.

By End-User

Based on end-user, the market is categorized into hospitals, specialty clinics, and others. The hospitals segment is expected to capture the largest brachytherapy market share of 69.80% by 2031. Hospitals are increasingly investing in brachytherapy equipment and technology to offer comprehensive cancer care, supported by the growing demand for minimally invasive, targeted therapies.

Enhanced by the ability to deliver precise radiation with minimal side effects, brachytherapy is becoming a preferred choice for treating various cancers. Additionally, the integration of brachytherapy into hospital treatment protocols and the increasing number of specialized cancer centers are boosting the growth of the segment. As hospitals expand their capabilities and upgrade their technology, they are experiencing significant expansion.

Brachytherapy Market Regional Analysis

Based on region, the global market is classified into North America, Europe, Asia-Pacific, MEA, and Latin America.

North America brachytherapy market share stood around 34.22% in 2023 in the global market, with a valuation of USD 336.9 million. This notable expansion is largely attributed to the rising cancer incidence rates and the early adoption of advanced technologies. The United States, in particular, plays a major role in this growth due to its large patient population and well-established healthcare infrastructure. The high prevalence of cancers, such as breast cancer, has led to increased demand for brachytherapy as an effective treatment option.

• The American Cancer Society estimated that about 1 in 8 women in the U.S. are likley to develope invasive breast cancer during their lifetime. In 2022, there were approximately 287,850 new cases reported.

This high incidence rate, coupled with the significant number of new cases of non-invasive breast cancer, contributes to the growing demand for brachytherapy solutions in the region. Furthermore, the integration of advanced brachytherapy technologies and increased funding for research and development, significantly contributes to regional market growth.

Asia-Pacific is anticipated to witness significant growth at a CAGR of 8.95% over the forecast period. The region is experiencing significant growth due to rising cancer incidences and advancements in healthcare infrastructure. Countries such as China, India, Japan, and South Korea are supporting this trend through their expanding healthcare sectors and increased investments in advanced medical technologies.

In China, the vast population and improved diagnostic capabilities facilitate the adoption of brachytherapy, while India’s focus on modern cancer care boosts demand. Japan and South Korea's sophisticated healthcare systems further bolster regional market growth. Moreover, government initiatives and funding for cancer treatment innovation contribute to the increasing use of brachytherapy in the region.

Competitive Landscape

The global brachytherapy market report will provide valuable insight with an emphasis on the fragmented nature of the industry. Prominent players are focusing on several key business strategies such as partnerships, mergers and acquisitions, product innovations, and joint ventures to expand their product portfolio and increase their market shares across different regions.

Companies are implementing impactful strategic initiatives, such as expanding services, investing in research and development (R&D), establishing new service delivery centers, and optimizing their service delivery processes, which are likely to create new opportunities for market growth.

List of Key Companies in Brachytherapy Market

• Eckert & Ziegler BEBIG
• Elekta AB
• Theragenics Corp.
• Becton, Dickinson, and Co.
• Varian Medical Systems Inc.
• iCAD Inc.
• CIVCO Medical Solutions
• Sun Nuclear Corp.
• AngioDynamics Inc.
• Hologic, Inc.

Key Industry Development

• October 2023 (Acquisition): Elekta announced the acquisition of the Xoft business from iCAD, Inc. through an asset acquisition. By acquiring the Xoft Axxent Electronic Brachytherapy (eBx) System and transferring employees, Elekta was able to offer electronic brachytherapy technology and provide an expanded range of cancer treatment options.

The global brachytherapy market is segmented as:

By Product Type

• Seeds
• Applicators and Afterloaders
• Electronic Brachytherapy

By Therapy

• Internal Radiation Therapy
• Intracavity Brachytherapy
• Interstitial Brachytherapy
• Episcleral brachytherapy
• External Radiation Therapy

By Dosage Type

• Low-dose Rate (LDR) Implants
• High-dose Rate (HDR) Implants
• Permanent implants

By Application

• Prostate Cancer
• Cervical Cancer
• Breast Cancer
• Lung Cancer
• Rectal Cancer
• Others

By End-User

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • U.K.
  • Spain
  • Germany
  • Italy
  • Russia
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Middle East & Africa
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America